JP2018517704A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018517704A5 JP2018517704A5 JP2017562664A JP2017562664A JP2018517704A5 JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5 JP 2017562664 A JP2017562664 A JP 2017562664A JP 2017562664 A JP2017562664 A JP 2017562664A JP 2018517704 A5 JP2018517704 A5 JP 2018517704A5
- Authority
- JP
- Japan
- Prior art keywords
- oligonucleotide
- composition
- mir
- nucleotide
- oligonucleotide inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 108091034117 Oligonucleotide Proteins 0.000 claims description 59
- 239000003112 inhibitor Substances 0.000 claims description 59
- 239000002773 nucleotide Substances 0.000 claims description 36
- 125000003729 nucleotide group Chemical group 0.000 claims description 36
- 108091033773 MiR-155 Proteins 0.000 claims description 21
- 230000000694 effects Effects 0.000 claims description 19
- 108090000623 proteins and genes Proteins 0.000 claims description 17
- 108020004414 DNA Proteins 0.000 claims description 15
- 102000053602 DNA Human genes 0.000 claims description 15
- 210000004027 cell Anatomy 0.000 claims description 15
- 210000003169 central nervous system Anatomy 0.000 claims description 14
- 230000014509 gene expression Effects 0.000 claims description 14
- 125000001921 locked nucleotide group Chemical group 0.000 claims description 12
- 208000012902 Nervous system disease Diseases 0.000 claims description 10
- 210000004969 inflammatory cell Anatomy 0.000 claims description 10
- 208000025966 Neurological disease Diseases 0.000 claims description 9
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims description 6
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 6
- 230000000295 complement effect Effects 0.000 claims description 6
- 210000000274 microglia Anatomy 0.000 claims description 4
- 210000001616 monocyte Anatomy 0.000 claims description 3
- 210000002569 neuron Anatomy 0.000 claims description 3
- 210000000278 spinal cord Anatomy 0.000 claims description 3
- 208000036110 Neuroinflammatory disease Diseases 0.000 claims description 2
- 230000003959 neuroinflammation Effects 0.000 claims description 2
- 239000000203 mixture Substances 0.000 claims 18
- 230000007115 recruitment Effects 0.000 claims 1
- 238000000034 method Methods 0.000 description 32
- 150000001875 compounds Chemical class 0.000 description 5
- 230000013632 homeostatic process Effects 0.000 description 4
- 230000002669 organ and tissue protective effect Effects 0.000 description 2
- 102100034798 CCAAT/enhancer-binding protein beta Human genes 0.000 description 1
- 101150053778 CSF1R gene Proteins 0.000 description 1
- 101150059254 Cux1 gene Proteins 0.000 description 1
- 101150050733 Gnas gene Proteins 0.000 description 1
- 101000945963 Homo sapiens CCAAT/enhancer-binding protein beta Proteins 0.000 description 1
- 101150080778 INPP5D gene Proteins 0.000 description 1
- 101150022636 MAFB gene Proteins 0.000 description 1
- 101150083522 MECP2 gene Proteins 0.000 description 1
- 101150082764 MR1 gene Proteins 0.000 description 1
- 101100298093 Mus musculus Pnkd gene Proteins 0.000 description 1
- 101100189144 Mus musculus Serpine1 gene Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101150116584 Rapgef5 gene Proteins 0.000 description 1
- 101150093886 TGFBR2 gene Proteins 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 101150034865 mef2a gene Proteins 0.000 description 1
- 101150013771 olfml3 gene Proteins 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562171743P | 2015-06-05 | 2015-06-05 | |
| US62/171,743 | 2015-06-05 | ||
| PCT/US2016/035794 WO2016196978A1 (en) | 2015-06-05 | 2016-06-03 | Mir-155 inhibitors for treating amyotrophic lateral sclerosis (als) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018517704A JP2018517704A (ja) | 2018-07-05 |
| JP2018517704A5 true JP2018517704A5 (enExample) | 2019-07-04 |
Family
ID=57442041
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017562664A Pending JP2018517704A (ja) | 2015-06-05 | 2016-06-03 | 筋萎縮性側索硬化症（ＡＬＳ）を処置するためのｍｉＲ−１５５阻害剤 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US20180161357A1 (enExample) |
| EP (1) | EP3303589A4 (enExample) |
| JP (1) | JP2018517704A (enExample) |
| CN (1) | CN107922947A (enExample) |
| CA (1) | CA2986913A1 (enExample) |
| WO (1) | WO2016196978A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013055865A1 (en) | 2011-10-11 | 2013-04-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| RU2718534C2 (ru) | 2015-06-05 | 2020-04-08 | Мираджен Терапьютикс, Инк. | Ингибиторы mir-155 для лечения кожной t-клеточной лимфомы (ctcl) |
| EP3526319B1 (en) | 2016-10-14 | 2025-12-10 | Children's Medical Center Corporation | Compositions and methods for treating diseases and disorders of the central nervous system |
| EP3571310A4 (en) | 2017-01-17 | 2020-12-16 | Children's Medical Center Corporation | COMPOSITIONS AND METHODS FOR DIAGNOSIS AND TREATMENT OF PEROXYSOMAL DISEASES |
| CA3050691A1 (en) | 2017-01-17 | 2018-07-26 | Dana-Farber Cancer Institute, Inc. | Compositions and methods for treating lysosomal storage diseases and disorders |
| US12144822B2 (en) | 2018-04-03 | 2024-11-19 | Academia Sinica | Mir-17˜92 as therapeutic or diagnostic target of motor neuron (MN) degeneration diseases |
| JP7499754B2 (ja) * | 2018-08-23 | 2024-06-14 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブ | Ｍｉｃｒｏｒｎａ－１３４バイオマーカー |
| WO2021067613A1 (en) * | 2019-10-01 | 2021-04-08 | Children's Medical Center Corporation | Compositions and methods for treating amyotrophic lateral sclerosis |
| CN114272378B (zh) * | 2020-09-27 | 2023-06-23 | 四川大学华西医院 | 一种使cttnbp2nl功能缺失的试剂在制备治疗疾病的药物中的用途 |
| CN112587662A (zh) * | 2020-12-22 | 2021-04-02 | 上海市徐汇区中心医院 | 一种miR-155/PEA15信号通路抑制剂在病理性心脏重构药物中的应用 |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101437942A (zh) * | 2006-04-03 | 2009-05-20 | 桑塔里斯制药公司 | 包含抗微小rna反义寡核苷酸的药物组合物 |
| MX2008012219A (es) * | 2006-04-03 | 2008-10-02 | Santaris Pharma As | Composicion farmaceutica que comprende oligonucleotidos antisentido anti-miarn. |
| ES2406686T3 (es) * | 2007-10-04 | 2013-06-07 | Santaris Pharma A/S | Micromirs |
| EP2268811A1 (en) * | 2008-03-07 | 2011-01-05 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of microrna related diseases |
| US9493834B2 (en) * | 2009-07-29 | 2016-11-15 | Pharnext | Method for detecting a panel of biomarkers |
| WO2013055865A1 (en) * | 2011-10-11 | 2013-04-18 | The Brigham And Women's Hospital, Inc. | Micrornas in neurodegenerative disorders |
| WO2013134403A1 (en) * | 2012-03-06 | 2013-09-12 | The Washington University | Method of treating neurodegenerative diseases with microrna regulators |
-
2016
- 2016-06-03 CA CA2986913A patent/CA2986913A1/en not_active Abandoned
- 2016-06-03 EP EP16804549.0A patent/EP3303589A4/en not_active Withdrawn
- 2016-06-03 WO PCT/US2016/035794 patent/WO2016196978A1/en not_active Ceased
- 2016-06-03 US US15/579,718 patent/US20180161357A1/en not_active Abandoned
- 2016-06-03 CN CN201680038698.3A patent/CN107922947A/zh active Pending
- 2016-06-03 JP JP2017562664A patent/JP2018517704A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018517704A5 (enExample) | ||
| Crow et al. | Targeting of type I interferon in systemic autoimmune diseases | |
| US20190062740A1 (en) | COMPOSITIONS AND METHODS OF USING piRNAS IN CANCER DIAGNOSTICS AND THERAPEUTICS | |
| WO2013055865A1 (en) | Micrornas in neurodegenerative disorders | |
| JP2016502858A5 (enExample) | ||
| US12203071B2 (en) | Oligonucleotide agonists targeting progranulin | |
| JP2016522674A5 (enExample) | ||
| JP2016116520A5 (enExample) | ||
| JP2015523854A5 (enExample) | ||
| JP2017532961A5 (enExample) | ||
| JP2018519835A5 (enExample) | ||
| KR20180081616A (ko) | 항-vegf로 치료된 연령-관련 황반 변성을 앓고 있는 환자에서의 임상 결과와 유전적 변이체를 연관시키는 방법 | |
| JP2021500016A5 (enExample) | ||
| WO2017192662A2 (en) | Methods for identifying treatment targets based on multiomics data | |
| Saeed | Lupus pathobiology based on genomics | |
| JP2013507127A5 (enExample) | ||
| US20200407721A1 (en) | Compounds of chemically modified oligonucleotides and methods of use thereof | |
| Wu et al. | Effect of miR-513a-5p on etoposide-stimulating B7-H1 expression in retinoblastoma cells | |
| JP2019523302A5 (enExample) | ||
| EP3773585A1 (en) | Compositions and methods for treating cancer | |
| JP6049143B2 (ja) | オリゴヌクレオチド、グルココルチコイド感受性増強剤、医薬組成物、及び発現ベクター | |
| Sanchez et al. | Characterization of frataxin gene network in Friedreich's ataxia fibroblasts using the RNA-Seq technique | |
| ZHANG et al. | Analysis of DNA methylation of CD79B in MDV-infected chicken spleen | |
| US20140193366A1 (en) | Modulators of miR-323-3p for the Prevention or Treatment of Rheumatoid Arthritis | |
| Mustafin | The role of transposable elements in the association of polymorphic variants with multifactorial diseases |